Angle PLC New Research with Parsortix
September 04 2017 - 1:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
04 September 2017
For immediate release 4 September 2017
ANGLE plc ("the Company")
NEW RESEARCH WITH PARSORTIX DEMONSTRATES ABILITY TO IDENTIFY KEY
PROTEINS INVOLVED IN BREAST CANCER CELL GROWTH AND SURVIVAL
Parsortix harvests relevant cells missed by antibody-based
systems
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy
company, is pleased to announce the publication of research by
Heinrich Heine University of Duesseldorf (Duesseldorf)
demonstrating the measurement of key proteins in breast cancer
using Parsortix, which may advise therapy decisions in breast
cancer treatment.
The research has been published in the International Journal of
Molecular Science and is available at
http://angleplc.com/library/publications/.
Duesseldorf have shown in their study of 47 metastatic breast
cancer patients that the Parsortix system harvests clinically
relevant cancer cells for analysis that other systems miss (EpCAM
low/negative CTCs) and confirmed this by demonstrating that
Parsortix can harvest such cells from the waste product of the
leading antibody-based system.
Duesseldorf established protocols combining Parsortix with the
downstream CellCelector micromanipulator to enable the individual
processing of CTCs (circulating tumour cells) as single cells so
that the heterogeneity of the patient's cancer can be investigated.
The downstream analysis included Sanger sequencing investigating
the presence or absence of PIK3CA, one of the most frequently
mutated genes in invasive breast cancer which confers remarkable
selective growth gain to the cell.
In the publication, the researchers state that the mutational
analysis of the PIK3CA within EpCAM low/negative CTCs (i.e. CTCs
that can be harvested by Parsortix but not by antibody-based
systems) may allow personalised HER2-targeted therapies.
Duesseldorf is a customer of ANGLE and its research work is
independent of the Company.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"These results published in a leading peer-reviewed journal are
further demonstration of the key advantages of the Parsortix
system. Our strategy of getting the Parsortix system widely used in
leading cancer research centres is working well with customers
driving growth in the body of evidence behind Parsortix."
For further information:
ANGLE plc +44 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser),
Steve Cox
Russell Kerr (Sales) +44 20 7397 8900
WG Partners
David Wilson
Claes Spång +44 20 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert +44 20 3727 1000
Kimberly Ha (US) +1 212 850 5612
About ANGLE plc
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADBGDCGBGBGRX
(END) Dow Jones Newswires
September 04, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024